Figure 1.

The expression of DIRAS3 is clinically correlated with the malignant progression in patients with lung cancer

(A) Boxplots of DIRAS3 mRNA levels determined from 5 Oncomine datasets, namely Wachi, Hou, Landi, Okayama, and Selamat (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001; p-values were obtained using two-tailed Student’s t-tests).

(B) Representative IHC images showing the DIRAS3 expression in 32 normal and 154 NSCLC samples.

(C) Immunoreactivity scores (IRS) of DIRAS3 in 32 normal and 154 NSCLC samples were shown as a histogram (∗∗∗p < 0.001; p-value was calculated via two-tailed Student’s t test).

(D) Kaplan-Meier plots of the overall survival (OS) of all patients stratiFIed by DIRAS3 expression. The data were acquired from the Kaplan-Meier plotter database (p-value was obtained using the log rank test).